News

Ace-ER is designed to replace the deficient sialic acid substrate in patients with GNE Myopathy, also known as Hereditary Inclusion Body Myopathy (HIBM), a rare, progressive muscle-wasting disease.

In an effort to improve the quality of life for patients suffering from this debilitating disorder, a research team of investigators at Boehringer Ingelheim, the Universities of Michigan

This catalog and its associated materials are called the Amgen Biology-Enabling Resource (AmBER). AmBER is comprised of more than 1,000 elements and includes small molecules, peptides, antibodies and

In patients with active cancer, the risk of venous thromboembolism (VTE) is four to seven times higher than in people of the same age without cancer, while chemotherapy

Under the multi-year program, the company will award a total of about $3m in grants to investigators in the US. This program is an extension of the company’s

Varlilumab is the company’s fully human monoclonal agonist antibody that binds and activates CD27, a critical co-stimulatory molecule in the immune activation cascade. The Phase I portion of

Synjardy is a combination of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and metformin hydrochloride (HCl), commonly prescribed to treat T2D. In the EU, empagliflozin was approved

Mircera is used to treat symptomatic anaemia associated with chronic kidney disease (CKD) in adult patients. The company said that the drug represents a complement to its existing

Zafatek (trelagliptin succinate) controls blood glucose levels by selectively and continually inhibiting DPP-4, an enzyme that causes the inactivation of glucagon-like peptide-1 and glucagon-dependent insulinotropic polypeptide, incretin hormones